True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmedmedication adherence

Journal of Hypertension

Volumn 33, Issue 12, 2015, Pages 2526-2533

  Beaussier, Hélène ^a   Boutouyrie, Pierre ^b,c,d   Bobrie, Guillaume ^b   Frank, Michael ^b   Laurent, Stéphane ^b,c,d   Coudoré, François ^a   Azizi, Michel ^b,c  

^a SAINT JOSEPH HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

antihypertensive drugs; hypertension; left ventricular mass; medication adherence; pulse wave velocity

Indexed keywords

AMILORIDE; AMLODIPINE; BISOPROLOL; CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; RAMIPRIL; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CONCENTRATION; ECHOCARDIOGRAPHY; ELECTROLYTE BALANCE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SEQUENTIAL NEPHRON BLOCKADE; SEQUENTIAL RENIN ANGIOTENSIN SYSTEM BLOCKADE; TONOMETRY; TREATMENT DURATION; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; CORONARY VASOSPASM; DRUG EFFECTS; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MIDDLE AGED; NEPHRON; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CORONARY VASOSPASM; DIURETICS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEPHRONS; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84947020250     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000737     Document Type: Article

References (41)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
3. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070.
4. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012; 380:591-600.
5. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:1957-1965.
6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
7. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
8. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30:1656-1664.
9. Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Menard J, et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens 2014; 32:2038-2044; [discussion 44].
10. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100:855-861.
11. Strauch B, Petrak O, Zelinka T, Rosa J, Somloova Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31:2455-2461.
12. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766-774.
13. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200-209.
14. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens 2009; 11:376-382.
15. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005; 25:135-143.
16. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23:2093-2100.
17. Romanelli RJ, Schiro TA, Jukes T, Wong KS, Ishisaka DY. Disparities in blood pressure control within a community-based provider network: an exploratory analysis. Ann Pharmacother 2011; 45:1473-1482.
18. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107.
19. Yiannakopoulou E, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prevent Rehabil 2005; 12:243-249.
20. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62:218-225.
21. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens 2012; 14:694-700.
22. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30:1015-1019.
23. Bobrie G, Weber JL, Postel-Vinay N, Menard J, Plouin PF. Teletransmission of home blood pressure monitoring: making it easier. J Hypertens 2008; 26:1046-1047; [discussion 8].
24. Staessen JA, Beilin L, Parati G, Waeber B, White W. Task force IV: clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit 1999; 4:319-331.
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
26. Coudore F, Harvard L, Lefeuvre S, Billaud E, Beaune P, Bobrie G, et al. HPLC-DAD analysis of hydrochlorothiazide and irbesartan in hypertensive patients on fixed-dose combination therapy. Chromatographia 2011; 74:559-565.
27. Azizi M, Menard J, Peyrard S, Lievre M, Marre M, Chatellier G. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. Diab Care 2006; 29:1331-1336.
28. WHO. Adherence to long-term therapies: evidence for action. http:// www. who. int/chp/knowledge/publications/adherence-introduction. pdf [Accessed 06 August 2015].
29. Reference Values for Arterial Stiffness C. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31:2338-2350.
30. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30:445-448.
31. Bunker J, Callister W, Chang CL, Sever PS. How common is true resistant hypertension? J Hum Hypertens 2011; 25:137-140.
32. Pladevall M, Brotons C, Gabriel R, Arnau A, Suarez C, de la Figuera M, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). Circulation 2010; 122:1183-1191.
33. Berni A, Ciani E, Cecioni I, Poggesi L, Abbate R, Boddi M. Adherence to antihypertensive therapy affects Ambulatory Arterial Stiffness Index. Eur J Internal Med 2011; 22:93-98.
34. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation 2001; 103:987-992.
35. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
36. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349.
37. Mancia G. Additional drug treatment in resistant hypertension: need for randomized studies. J Hypertens 2012; 30:1514-1515.
38. Santschi V, Wuerzner G, Schneider MP, Bugnon O, Burnier M. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol 2007; 63:1179-1184.
39. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
40. Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, et al. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens 2012; 14:429-434.
41. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73:691-705.